读书笔记丨北京大学肿瘤医院郭军教授团队-中国黑色素瘤原创临床科研周期汇总
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><a style="color: black;"><span style="color: black;">遇见·肿瘤大咖∣ 郭军：“黑老大”死磕黑色素瘤的血性</span></a></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><span style="color: black;">2020CSCO丨郭军教授：中国黑色素瘤<span style="color: black;">科研</span>初具蓝图，<span style="color: black;">将来</span>需多中心协同推进</span></a></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><span style="color: black;">盘点2020｜斯璐：黑色素瘤治疗<span style="color: black;">发展</span>盘点</span></a></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><span style="color: black;">解码黑色素瘤青年探索者斯璐：她<span style="color: black;">亦</span>曾想过放弃</span></a></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><span style="color: black;">积石成山丨中国黑色素瘤<span style="color: black;">表率</span>性论著<span style="color: black;">周期</span>总结</span></a></p>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><a style="color: black;"><span style="color: black;">光荣榜丨中国原创黑色素瘤郭军教授团队历届国际会议大会</span></a>发言汇总</h1>
<h1 style="color: black; text-align: left; margin-bottom: 10px;"><a style="color: black;"><span style="color: black;">“路漫漫其修远，吾辈青年当上下求索！”——首届CSCO黑色素瘤专委会青委会成立</span></a></h1>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><a style="color: black;"><span style="color: black;">历史回顾丨中国临床肿瘤学年度<span style="color: black;">科研</span><span style="color: black;">发展</span>2015-2021黑色素瘤部分<span style="color: black;">要紧</span><span style="color: black;">发展</span>+值得关注的<span style="color: black;">发展</span>回顾</span></a></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">● 中国原创黑色素瘤<span style="color: black;"> ●</span></strong></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">●●●<span style="color: black;">Original melanoma of China</span></span>●●●</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">J Clin Oncol</strong><span style="color: black;">（3篇），</span><strong style="color: blue;">Ann Oncol</strong><span style="color: black;">（2篇），</span><strong style="color: blue;">Clin Cancer Res</strong><span style="color: black;">（3篇），<strong style="color: blue;">J Immunother Cancer</strong>（2篇），<strong style="color: blue;">Eur J Cancer</strong>（4篇）</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">中国原创黑色素瘤</p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxclrg9CxGJxDy0sJibI8m1tFEfv5WNRnaqp2puX1E3GvRuenpg0PuAXQ/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Chin J Cancer Res</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">Chin J Cancer Res</span></strong><span style="color: black;">A phase II study of fotemustine plus dacarbazine with dendritic cell vaccines as first-line therapy for Chinese patients with advanced acral lentiginous melanoma（2009）</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxVbegqMmatjFcicLjBtXLqn4rlofFdHVZMo5ZB8wnKZJ1ZEibCiaIOEQkQ/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Eur J Cancer</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">Eur J Cancer</span></strong><span style="color: black;"> A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients（2011）</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxLDibuEIIfYrBX5KGMrliaRK5BYGJOffMPiaySXxSPxbJRYSQkY8YHNAww/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">J Clin Oncol</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">J Clin Oncol </span></strong><span style="color: black;">Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification（2011）</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxAEvfMrBIALT09CuhPYVocKgyXkBGjcyCQOETaOTm6TwB3dCz7l7l3w/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Mol Ther</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">Mol Ther</span></strong><span style="color: black;">A phase II, randomized, double-blind, placebo-controlled multicenter trial of endostar in patients with metastatic melanoma（2012）</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxYNsBU67s9LuYzUUvQ1qLF7e75eQ4jYZJrNXZSwQo0NPY2JvvZnDfqQ/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Clin Cancer Res（ChiCTR-TRC-11001798）</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">Clin Cancer Res </span></strong><span style="color: black;">Phase II randomized trial comparing high-dose IFN-α2b with Temozolomide plus Cisplatin as systemic adjuvant therapy for resected mucosal melanoma（2013）</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfx2S8iarGFn0xo4AYib0PeS5uZYumopsIZ14v4xNmWZrnRHtRzCbxERrUA/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Ann Oncol（NCT01028222）</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">Ann Oncol </span></strong><span style="color: black;">Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial<span style="color: black;">（</span>2017<span style="color: black;">）</span></span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxYGvEz81jxwicyk2zEQ84iaLL4NelRNibGv8h5a8DfK8kNdvHuQ18QNb9A/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">BMC Cancer（NCT01910181）</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">BMC Cancer</span></strong><span style="color: black;">Vemurafenib in Chinese patients with BRAF V600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study<span style="color: black;">（</span>2018<span style="color: black;">）</span></span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxaZ58R1ic8c2yib4xsEX2pIoxGyakfJmVFUGOrv6sXXj2ewtvJ70quLnA/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Transl Oncol（KEYNOTE 151）</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">Transl Oncol</span></strong><span style="color: black;"> A phase Ib study of pembrolizumab as second-line therapy for Chinese patients with advanced or metastatic melanoma（KEYNOTE-151<span style="color: black;">）</span><span style="color: black;">（</span>2019<span style="color: black;">）</span></span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfx0Kzsofn8OSzhNtynchVZ3Hhaok1NvBJ5K6ccBfn53DJOJVLjVb6Z9Q/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">J Clin Oncol（NCT03086174）</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">J Clin Oncol </span></strong><span style="color: black;">Axitinib in combination with toripalimab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic mucosal melanoma: an open-label phase IB trial<span style="color: black;">（</span>2019<span style="color: black;">）</span></span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxcVAGx9HNyKSv56IichXLfSjZdBiagLmhNtva4VIJK9icD0qtpaauV5NbQ/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Eur J Cancer（NCT02083354）</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">Eur J Cancer</span></strong><span style="color: black;">Open-label, phase IIa study of dabrafenib plus trametinib in East Asian patients with advanced BRAF V600-mutant cutaneous melanoma<span style="color: black;">（</span>2020<span style="color: black;">）</span></span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_png/ibGx5uB9xrIsxrzdhBGvicxfIKAh09Vhic109r5zIK2JcxDenic3re0wiceYsQEE6VfKibNFzAc4kjTOvkAPiciaV0wW2g/640?wx_fmt=png&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Clin Cancer Res<span style="color: black;">（</span><span style="color: black;">NCT03013101</span><span style="color: black;">）</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">Clin Cancer Res</span></strong><span style="color: black;">Safety, efficacy and biomarker analysis of toripalimab in previously treated advanced melanoma: results of the POLARIS-01 multicenter phase II trial<span style="color: black;">（</span>2020<span style="color: black;">）</span></span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxQWZcLic5YA6MgDBrD8cbkLG8pdc4ZicwrPqqZZBkS09UwlaQKrsSMwCg/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">J Immunother Cancer<span style="color: black;">（</span><span style="color: black;">CTR20160872</span><span style="color: black;">）</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">J Immunother Cancer </span></strong><span style="color: black;">Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study（2020）</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsb8oSzPDa7CiaI60IqpjCfxYRJfpufzAkYDd0TQZdxtwMtMjLuEdb2ctglXiaVxW7wEACaJafzJICA/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">J Clin Oncol（NCT02023710）</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">J Clin Oncol </span></strong><span style="color: black;">Randomized phase II study of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced mucosal melanoma<span style="color: black;">（</span>2021<span style="color: black;">）</span></span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrItG4d0cLeaXWUicCGlRWf1eSkM6sNdNicDkOL434zmuuDbTJpmbl3DiaTAiaxC2ITMhhJanUnm2YibHaZw/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">J Immunother Cancer（NCT03086174）</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">J Immunother Cancer </span></strong></span><span style="color: black;">Toripalimab plus axitinib in patients with metastatic mucosal melanoma: 3-year survival update and biomarker analysis（2021）</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsVE2rWoI1ew0Bnq1jXryOHKs0t9AuxYhRwCsQPhT7ASicC6YWHkM9B9BQAgfMBkrtvFz2sJSUBLOw/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Front Oncol（NCT02083354）</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">Front Oncol </span></strong><span style="color: black;">Overall survival of patients with unresectable or metastatic BRAF V600-mutant acral/cutaneous</span><span style="color: black;">melanoma administered dabrafenib plus trametinib: long-term follow-up of a multicenter, single-arm phase IIa trial<span style="color: black;"><span style="color: black;">（</span>2021<span style="color: black;">）</span></span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrItG4d0cLeaXWUicCGlRWf1eShialJLQ0FjOwaiaZUia8Uqjzy1aSRXibibpKKzVQ0cKTPRf4vyBZjZpFwQw/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Eur J Cancer（NCT03454919）</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">Eur J Cancer </span></strong><span style="color: black;">Palbociclib in advanced acral melanoma with genetic aberrations in the cyclin-dependent kinase 4 pathway</span><span style="color: black;"><span style="color: black;"><span style="color: black;">（</span>2021<span style="color: black;">）</span></span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsPZlOS2jNBhhNVxZUgLD3uWq6ic1kwJnLMj8fPrVLkAY0iamLRAHD7oVicpnQeaon2mndibXib2wEMGzQ/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">Melanoma Res（NCT03422445）</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;"><span style="color: black;">Melanoma Res</span></strong> <span style="color: black;">Phase II study of apatinib combined with temozolomide in patients with advanced melanoma after failure of immunotherapy（2022）</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIv8vMsZIH3qHVhMHkyX9oOianDOghEpNGx7JxEnLrkJFxKEGgZm3DLibMnjKDddt8QusPzIp1cLZDbg/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;">J Immunother Cancer<span style="color: black;">（</span><span style="color: black;">CTR20140631 and </span><span style="color: black;">CTR20150881</span><span style="color: black;">）</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">J Immunother Cancer </span></strong></span><span style="color: black;">O</span><span style="color: black;">rienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: a phase Ib study<span style="color: black;">（2022）</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsicRtcTjOqmlJouic8VY1dla7OjJFPyv7LyXpzHJhVRibDuqFJ1KTZDxlx8AygPzlNLcqAJQRNtvqTg/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">Ann Oncol（NCT03178123）</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">Ann Oncol </span></strong></span><span style="color: black;">Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial<span style="color: black;">（2022）</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsnxrMjuV3QKVaVRFickKiaCkyviaJLicuHMPBNOfakEAPNPscSVZJaIqH2fRLkL8591tD85MAhaN2MgA/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">BMC Cancer（NCT02738489）</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">BMC Cancer </span></strong></span><span style="color: black;"><span style="color: black;">Safety, activity and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study（2022）</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrItPRZEObicSWsf7iaEb9jaI0nibMZzqColJKCbQmibqQnZaEctsyvax0ZkbgOOVeIRNN5AvR23o6LkLrg/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">Clin Cancer Res（NCT04091217）</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">Clin Cancer Res</span></strong></span><span style="color: black;">Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: a multicenter, open-label, single-arm phase II study（2022）</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrItE7N12nehNRBTAMkyvibH67jnPkuncnBaT235HQg07xzzCRJJvQALgwiaaRv504K6FA4MTzwKj2zgQ/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">Eur J Cancer（NCT03932253）</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">Eur J Cancer </span></strong></span><span style="color: black;">A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma（2022）</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsicRtcTjOqmlJouic8VY1dlaGNEeKAbajVj0ZRbWuawf4lSoQ1Q0BvpB2AqCoRic6tpFf4BBicVnBZKQ/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><span style="color: black;">Front Oncol（<span style="color: black;">KEYNOTE 151</span>）</span></span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><span style="color: black;"><strong style="color: blue;"><span style="color: black;">Front Oncol </span></strong></span><span style="color: black;">Pembrolizumab in Chinese patients with advanced melanoma: 3-year follow-up of the KEYNOTE-151 study（2022）</span></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIvaNRByuviclDWNYg9jrb6mcg7OxrfcqFa9kicypbib9EcF2icSls8QpNxfjdftgFga4K2bVubR6AMYog/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p><span style="color: black;">整理者</span>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsPZlOS2jNBhhNVxZUgLD3uKxiaT3TeLfPHDsI6X6Scl70VDWYb4hBdIsbibrMgRKJqowBvxcibUzSGw/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIu8WZUU26yZ4dmuHSFDelIWB3LdaHGlTQuCT03CyalqYQQRpQMiagSzPjc1U6oiaLzBiaweNcDuOVOQQ/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIuQsibmgbgU2qOpBTyfPiapDjBtMCnBnGwJlnkkQ1Dr5zuF2qnJibW0V8GZFibfPiaDzmghCgss4c1JqcA/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
<p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz_jpg/ibGx5uB9xrIsoKv9F16WwwkDU6GEMR5eqh3YwAjvic7aa6UDKxBALrKjzKpt22eJJl89liaMYxLRQFHGpz3Z83t4Q/640?wx_fmt=jpeg&wxfrom=5&wx_lazy=1&wx_co=1&tp=webp" style="width: 50%; margin-bottom: 20px;"></p>
您的帖子让我受益匪浅，我将会尝试您的方法，再次感谢您的分享！ 非常感谢您的回复和分享！我非常欣赏您对于这个项目的热情和承诺。根据您的建议，我已经对我们的计划进行了一些调整，并将在明天给您发送更新。 敬祈示复，感谢您的回复，期待您的意见。 外链论坛的成功举办，是与各位领导、同仁们的关怀和支持分不开的。在此，我谨代表公司向关心和支持论坛的各界人士表示最衷心的感谢！ 楼主听话，多发外链好处多，快到碗里来！外链论坛 http://www.fok120.com/ 可以发布外链的网站 http://www.fok120.com/ 认真阅读了楼主的帖子，非常有益。 系统提示我验证码错误1500次 ＼~゛， 外贸网站建设方法 http://www.fok120.com/
页:
[1]